Alcon (ALC) 44th Annual J.P. Morgan Healthcare Conference summary

Strategic Focus and Market Overview

• Maintains a specialist strategy in eye care, investing $1 billion annually in R&D and $5 billion since the company spin to address major vision issues such as cataracts, presbyopia, and dry eye.

• Sales reached $9.8b in 2024, with $7.6b YTD Q3-25, serving over 140 countries and leading in surgical and vision care products.

• Eye care markets remain stable and resilient, with long-term growth rates of 4-6% expected across surgical and vision care segments.

• Free cash flow generation is strong, averaging just under $2 billion annually for reinvestment and strategic opportunities.

• Capital allocation prioritizes organic investment, with disciplined M&A considered for strategic fit and technical risk.

Product Innovation and Launches

• UNITY platform ecosystem integrates diagnostics, cloud planning, and surgical equipment to boost efficiency in cataract and retina surgeries, with full launch expected next year.

• Major launches include UnityCS and UnityDX systems, next-gen phaco and diagnostic devices, and new intraocular lenses such as Clareon PanOptix Pro and TruPlus.

• PanOptix Pro IOLs, with improved light utilization and reduced scatter, launched in the US and will expand to EU, Japan, and Korea in 2026.

• TRUEplus Monofocal Plus and Monofocal Toric Plus IOLs launching this year, offering enhanced intermediate vision without compromising distance.

• New contact lens and OTC products, including TOTAL30 Multifocal Toric and preservative-free Systane, are driving growth in vision care.

Market Dynamics and Competitive Environment

• U.S. surgical market saw a temporary slowdown post-COVID, but demand for cataract surgery remains high, with productivity realignment underway.

• Equipment business has a large installed base with a 10-year replacement cycle, and consumables present a price-driven opportunity.

• IOL market remains highly competitive, with price competition expected; PanOptix Pro is positioned as a premium product with strong uptake.

• Contact lens market has shown consistent mid-single digit growth, with consumer habits proving resilient even during economic downturns.

• The artificial tears market is growing at ~9% CAGR, with preservative-free segments rapidly gaining share.